Last reviewed · How we verify

paclitaxel/Gemcitabine/Liposomal doxorubicin

Innovent Biologics (Suzhou) Co. Ltd. · Phase 3 active Small molecule

paclitaxel/Gemcitabine/Liposomal doxorubicin is a Taxane, Nucleoside analog, Anthracycline antibiotic Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd.. It is currently in Phase 3 development for Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer.

Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA.

Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA. Used for Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer.

At a glance

Generic namepaclitaxel/Gemcitabine/Liposomal doxorubicin
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Drug classTaxane, Nucleoside analog, Anthracycline antibiotic
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Paclitaxel stabilizes microtubules, preventing cell division, while Gemcitabine is incorporated into DNA, causing chain termination. Liposomal doxorubicin's intercalation into DNA inhibits topoisomerase II, leading to DNA damage and apoptosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about paclitaxel/Gemcitabine/Liposomal doxorubicin

What is paclitaxel/Gemcitabine/Liposomal doxorubicin?

paclitaxel/Gemcitabine/Liposomal doxorubicin is a Taxane, Nucleoside analog, Anthracycline antibiotic drug developed by Innovent Biologics (Suzhou) Co. Ltd., indicated for Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer.

How does paclitaxel/Gemcitabine/Liposomal doxorubicin work?

Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA.

What is paclitaxel/Gemcitabine/Liposomal doxorubicin used for?

paclitaxel/Gemcitabine/Liposomal doxorubicin is indicated for Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer.

Who makes paclitaxel/Gemcitabine/Liposomal doxorubicin?

paclitaxel/Gemcitabine/Liposomal doxorubicin is developed by Innovent Biologics (Suzhou) Co. Ltd. (see full Innovent Biologics (Suzhou) Co. Ltd. pipeline at /company/innovent-biologics-suzhou-co-ltd).

What drug class is paclitaxel/Gemcitabine/Liposomal doxorubicin in?

paclitaxel/Gemcitabine/Liposomal doxorubicin belongs to the Taxane, Nucleoside analog, Anthracycline antibiotic class. See all Taxane, Nucleoside analog, Anthracycline antibiotic drugs at /class/taxane-nucleoside-analog-anthracycline-antibiotic.

What development phase is paclitaxel/Gemcitabine/Liposomal doxorubicin in?

paclitaxel/Gemcitabine/Liposomal doxorubicin is in Phase 3.

What are the side effects of paclitaxel/Gemcitabine/Liposomal doxorubicin?

Common side effects of paclitaxel/Gemcitabine/Liposomal doxorubicin include Neutropenia, Anemia, Thrombocytopenia, Fatigue, Nausea, Vomiting.

Related